Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2004

View Archived Issues

Enhancement of memory T-cells may improve vaccine therapies

New approvals for tamsulosin formulations

Promising results with small molecule MIF inhibitors in a preclinical model of colitis

Taiho patent covers new antiarthritic agents

Novel HDL-increasing agents developed at Eisai

Novel PDE4 inhibitors prepared and tested at Kyowa Hakko

Oxazepine-based antitumor agents newly discovered at Servier

Novel DPP-IV inhibitors and their use in type 2 diabetes claimed by Merck

New antitumor, antibacterial and antifungal agents isolated from Streptomyces sp.

Pfizer researchers describe new cannabinoid CB1 antagonists

Micrologix Biotech changes name to Migenix

Introgen Therapeutics receives NCI grant to further mda-7 gene research

Ceregene begins phase I trial of novel gene therapy for Alzheimer's disease

GSK grants Kenyan company license for manufacture and sale of HIV/AIDS medicines in Africa

Pharmion's MAA for Vidaza accepted for review by EMEA

Good safety profile reported for the NYVAC-HIVC vaccine in healthy volunteers

Phase II trial of Infecton for the detection of bacterial osteomyelitis initiated

Therapeutic benefits of SomatoKine in a child with Leprechaunism

E.U. approves Xenical label change

Clinical evidence for the efficacy of topiramate in the prevention of migraine

CytoVax and Millenium enter into definitive merger agreement

Phase I study for novel antibiotic WAP-8294A2 commences in U.S.

Fast track designation for Aurexis

FDA grants priority review to investigational female testosterone patch

Roche and Glycart to discover next-generation therapeutic antibodies

Enrollment completed for U.S. phase II Psoraxine study

GW-274150 reduces experimental neuropathic hypersensitivity

In vivo effects of capsaicin reduced by GW-833972

AF-3191 effective in preclinical pain models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...